Our team of highly skilled and experienced professionals is dedicated to delivering up-to-date and precise study materials in PDF format to our customers. We deeply value both your time and financial investment, and we have spared no effort to provide you with the highest quality work. We ensure that our students consistently achieve a score of more than 95% in the SCDM CCDM exam. You provide only authentic and reliable study material. Our team of professionals is always working very keenly to keep the material updated. Hence, they communicate to the students quickly if there is any change in the CCDM dumps file. The SCDM CCDM exam question answers and CCDM dumps we offer are as genuine as studying the actual exam content.
24/7 Friendly Approach:
You can reach out to our agents at any time for guidance; we are available 24/7. Our agent will provide you information you need; you can ask them any questions you have. We are here to provide you with a complete study material file you need to pass your CCDM exam with extraordinary marks.
Quality Exam Dumps for SCDM CCDM:
Pass4surexams provide trusted study material. If you want to meet a sweeping success in your exam you must sign up for the complete preparation at Pass4surexams and we will provide you with such genuine material that will help you succeed with distinction. Our experts work tirelessly for our customers, ensuring a seamless journey to passing the SCDM CCDM exam on the first attempt. We have already helped a lot of students to ace IT certification exams with our genuine CCDM Exam Question Answers. Don't wait and join us today to collect your favorite certification exam study material and get your dream job quickly.
90 Days Free Updates for SCDM CCDM Exam Question Answers and Dumps:
Enroll with confidence at Pass4surexams, and not only will you access our comprehensive SCDM CCDM exam question answers and dumps, but you will also benefit from a remarkable offer – 90 days of free updates. In the dynamic landscape of certification exams, our commitment to your success doesn't waver. If there are any changes or updates to the SCDM CCDM exam content during the 90-day period, rest assured that our team will promptly notify you and provide the latest study materials, ensuring you are thoroughly prepared for success in your exam."
SCDM CCDM Real Exam Questions:
Quality is the heart of our service that's why we offer our students real exam questions with 100% passing assurance in the first attempt. Our CCDM dumps PDF have been carved by the experienced experts exactly on the model of real exam question answers in which you are going to appear to get your certification.
SCDM CCDM Sample Questions
Question # 1
QUESTION 150
On a dose escalation study, the Data Manager notices one site has a much higher number of queries
than other sites and most are older than 30 days. The Data Safety Monitoring Board will meet in
three weeks. What should the Data Manager providing CRO oversight do?
A. Notify the CRO's Clinical Leader about the concerns B. Call the site directly and ask the study coordinator about the concerns C. Consult the CRO's Lead Data Manager and the CRO's Project Leader D. Ignore it for now and check back next week
Answer: C Explanation:
The correct action is to consult the CROs Lead Data Manager and CROs Project Leader (Option C) to
ensure the issue is addressed through the appropriate oversight and escalation process.
According to the GCDMP (Chapter: Project Management and Communication), when a sponsor Data
Manager identifies significant data management issues under CRO oversight ” such as aging queries
or site performance disparities ” communication must follow the established governance and
escalation pathway defined in the Scope of Work (SOW) and Data Management Plan (DMP).
Directly contacting the site (Option B) bypasses the CROs chain of command and violates
communication protocols. Notifying only the Clinical Leader (Option A) is insufficient, and ignoring
the issue (Option D) jeopardizes the Data Safety Monitoring Board (DSMB) review timeline.
Therefore, Option C ensures a documented, collaborative approach to problem resolution within the
contractual oversight structure.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Project Management and
Communication, Section 7.1 “ Oversight of CRO Data Management Activities
ICH E6 (R2) GCP, Section 5.2 “ Contract Research Organization Responsibilities
FDA Guidance for Industry: Oversight of Clinical Investigations “ Sponsor and CRO Roles and Communication Pathways
Question # 2
In reviewing the adverse events for a subject, a data manager notices one recorded as "worsening of
migraine." After reviewing the rest of the adverse events and finding no other migraine recordings,
what is the data manager's next step?
A. Look for any adverse event instance of headache and assume the events are similar. B. Query the site for the first adverse event occurrence of migraine. C. Check the medical history for recording of a history of migraines. D. Query the site for more information on the adverse event, "worsening of migraine."
Answer: D Explanation:
When a data inconsistency arises ” such as a record of œworsening of migraine without prior
documentation of a migraine episode ” the Data Manager should query the site for clarification (Option D).
According to the GCDMP (Chapter: Data Validation and Cleaning), data managers must raise a
clarification query whenever data appear incomplete, inconsistent, or ambiguous. The site must
confirm whether œworsening of migraine refers to a new event or an exacerbation of a preexisting
condition. This clarification ensures accurate safety reporting and appropriate medical coding (e.g., MedDRA classification).
Checking the medical history (Option C) may help but does not resolve the inconsistency. Assuming a
relationship (Option A or B) without verification would violate Good Clinical Data Management
Practice and potentially misrepresent the adverse event.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Validation and Cleaning, Section 6.3 “ Query Generation and
Resolution
ICH E2A “ Clinical Safety Data Management: Definitions and Standards for Expedited Reporting, Section II “ Data Clarification Requirements
FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations “ Data Query Management
Question # 3
What significant difference is there in the DM role when utilizing an EDC application?
A. Data updates are implemented by the sites B. Database validation is not required C. Metrics generation is required D. Tracking of eCRFs is a monitor's responsibility
Answer: A Explanation:
The most significant difference in the Data Managers role when using an Electronic Data Capture
(EDC) system is that data updates are implemented directly by site personnel (Option A).
According to the GCDMP (Chapter: Electronic Data Capture Systems), EDC technology shifts
responsibility for data entry and correction from the sponsor or CRO to the investigator site, enabling
real-time data entry and validation. This eliminates the need for double entry or remote data
transcription, allowing Data Managers to focus on system validation, query management, and data
quality oversight rather than physical data handling.
However, the EDC system still requires full validation (contrary to Option B). Metrics generation
(Option C) and CRF tracking (Option D) are important but not unique to EDC-based workflows.
Thus, the correct answer is Option A “ Data updates are implemented by the sites, reflecting the
most fundamental operational shift introduced by EDC systems.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Electronic Data Capture (EDC)
Systems, Section 4.1 “ Role of the Data Manager in EDC
ICH E6 (R2) GCP, Section 5.5.3 “ Electronic Data Entry and Responsibilities
FDA 21 CFR Part 11 “ Electronic Records and Signatures: Data Entry Responsibilities
Question # 4
Which protocol section most concisely conveys timing of data collection throughout a study?
A. Study endpoints section B. Study schedule of events C. Protocol synopsis D. ICH essential documents
Answer: B Explanation:
The Study Schedule of Events (SoE) section in the protocol is the most concise and comprehensive
representation of the timing of data collection throughout a study.
According to the Good Clinical Data Management Practices (GCDMP, Chapter: Data Management
Planning and Study Start-up) and ICH E6 (R2) GCP, the SoE outlines what assessments, procedures,
and data collections occur at each study visit (e.g., screening, baseline, treatment visits, follow-up).
This table is a foundational tool for CRF design, database structure, and edit-check development,
ensuring alignment between the protocol and data management systems. While the study endpoints section (A) defines what is measured, and the protocol synopsis (C)
summarizes the design, only the schedule of events (B) specifies when data collection occurs for each
parameter. The ICH essential documents (D) pertain to regulatory documentation, not study visit
timing.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Management Planning and
Study Start-up, Section 4.1 “ Using the Schedule of Events for Database Design
ICH E6 (R2) GCP, Section 6.3 “ Trial Design and Schedule of Assessments
FDA Guidance for Industry: Protocol Design and Data Collection Standards
Question # 5
A Data Manager is designing a report to facilitate discussions with sites regarding late dat
a. Which is the most important information to display on the report to encourage sites to provide
data?
A. Number of forms entered in the last week B. Expected versus actual forms entered C. List of outstanding forms D. Total number of forms entered to date
Answer: C Explanation:
In managing site data timeliness, the most actionable and effective tool is a report listing all
outstanding (missing or incomplete) CRFs.
According to GCDMP (Chapter: Communication and Study Reporting), Data Managers must provide
site-level performance reports highlighting:
Outstanding CRFs not yet entered,
Unresolved queries, and
Pending data corrections.
Such reports help sites prioritize and address data gaps efficiently.
Option A and D are historical metrics without actionable context.
Option B gives a general overview but lacks specific site-level actionability.
Hence, option C (List of outstanding forms) provides the clearest and most motivating feedback to
sites for timely data entry and query resolution.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Communication and Study Reporting, Section 5.3 “ Data Timeliness and
Reporting Metrics
ICH E6(R2) GCP, Section 5.1.1 “ Sponsor Oversight and Data Communication Requirements
FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6.5 “ SiteLevel Data Timeliness Reporting
Question # 6
For clinical investigational sites on an EDC trial, which of the following archival options allows
traceability of changes made to data?
A. Storing the computer used at the clinical investigational site B. Paper copies of the source documents C. PDF images of the final eCRF screens for each patient D. ASCII files of the site's data and related audit trails
Answer: D Explanation:
Regulatory agencies such as the FDA and ICH require that electronic data be retained in a format that
preserves audit trails and traceability.
While PDF images (option C) provide a static representation of data, they do not preserve the
underlying audit trail (i.e., who changed what, when, and why). The ASCII data files with
corresponding audit trails (option D) provide complete transparency and comply with 21 CFR Part 11
and GCDMP archival standards.
Option A (storing computers) is unnecessary and impractical, and Option B (paper source
documents) are site records, not system archives.
Hence, option D is correct ” ASCII data files with audit trails meet traceability and compliance
standards.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Database Lock and Archiving, Section 5.4 “ Archival Formats and Audit Trail
Retention
ICH E6(R2) GCP, Section 5.5.3 “ Data Integrity, Audit Trails, and Record Retention
FDA 21 CFR Part 11 “ Electronic Records; Audit Trail and Retention Requirements
Question # 7
A Data Manager is designing a CRF for a study for which the efficacy data are not covered by the
current SDTM domains. Which search should the Data Manager do?
A. Use controlled terminology covering the needed concepts B. Work with the study team to define new data elements C. Search for relevant data element standards D. Advise the study team not to collect the data
Answer: C Explanation:
When existing SDTM (Study Data Tabulation Model) domains do not cover specific efficacy data, the
best practice is to first search for relevant data element standards that may be available through
CDISC CDASH (Clinical Data Acquisition Standards Harmonization) or other recognized industry
standards.
Per GCDMP (Chapter: Standards and Data Integration), Data Managers must ensure that new CRF
elements are consistent with standardized definitions, controlled terminology, and data models to
support interoperability, future analysis, and regulatory submission.
If no existing standards exist, only then should the Data Manager collaborate with the study team to
define new elements ” but standard searches always come first.
Thus, option C is correct ” search for relevant data element standards ensures alignment with CDISC
best practices and regulatory expectations.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Standards and Data Integration, Section 5.1 “ Use of CDISC Standards in CRF
Design
CDISC CDASH Implementation Guide, Section 4.1 “ Standardization of Data Collection Fields
FDA Study Data Technical Conformance Guide (SDTCG), Section 2.4 “ Use of Standard and Custom
Domains
Question # 8
ePRO data are collected for a study using study devices given to subjects. Which is the most
appropriate quality control method for the data?
A. Programmed edit checks to detect out of range values after submission to the database B. Manual review of data by the site study coordinator at the next visit C. Data visualizations to look for site-to-site variation D. Programmed edit checks to detect out of range values upon data entry
Answer: D Explanation:
When electronic patient-reported outcomes (ePRO) devices are used, data are captured directly by
subjects through validated devices and transmitted electronically to the study database. To ensure
real-time data quality control, programmed edit checks should be implemented at the point of data
entry ” that is, as subjects input data into the device.
According to Good Clinical Data Management Practices (GCDMP, Chapter: Data Validation and
Cleaning), front-end programmed edit checks are the optimal method to prevent entry of invalid or
out-of-range values in ePRO systems. This helps maintain data accuracy at the source, minimizing
downstream queries and data cleaning workload.
Options A and B involve post-submission or manual review, which is less efficient and not compliant
with the principle of first-pass data validation. Option C (visualization) is a valuable secondary QC
method for trends, but not for immediate data validation.
Therefore, option D is correct ” programmed edit checks upon data entry ensure immediate validation and higher data integrity.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Data Validation and Cleaning, Section 5.3 “ Automated Edit Checks and
Front-End Validation
ICH E6(R2) GCP, Section 5.5.3 “ Computerized System Controls and Validation
FDA Guidance for Industry: Electronic Source Data in Clinical Investigations (2013), Section 6 “ RealTime Data Quality Control
Question # 9
Which action has the most impact on the performance of a relational database system?
A. Entering data into the database from CRFs B. Loading a large lab data file into the database C. Executing a properly designed database query D. Making updates to data previously entered into the database
Answer: B Explanation:
In a relational database system used in clinical data management, performance refers to how
efficiently the system processes transactions, retrieves data, and handles large volumes of
information without delay or data integrity issues. Among the listed options, loading a large lab data
file into the database (Option B) has the most significant impact on database performance.
According to the Good Clinical Data Management Practices (GCDMP, Chapter on Database Design
and Build), the bulk data load process ” such as importing large external datasets (e.g., central lab
data, ECG results, or imaging metadata) ” can be computationally intensive. This process engages
the databases input/output (I/O) subsystem, indexing mechanisms, and transaction logs
simultaneously, often locking tables temporarily and consuming significant memory and processing
resources.
Unlike standard CRF data entry (Option A) or record updates (Option D), which are incremental and
typically processed in smaller transactional batches, bulk loading operations handle thousands or
millions of rows at once. If not optimized (e.g., via staging tables, indexing strategies, or commit
frequency control), such operations can degrade system performance, slow down concurrent user
access, and increase the risk of transaction failure.
Executing a properly designed query (Option C) can also be resource-intensive depending on data volume and join complexity, but when queries are properly optimized (using indexed keys, efficient
SQL joins, and selective retrieval), their impact is generally controlled and transient compared to
large data imports.
Therefore, as outlined in the GCDMP Database Design and Build and FDA Computerized Systems
Guidance, the most performance-impacting activity in a relational database is bulk loading large
external datasets, making Option B the correct answer.
Reference (CCDM-Verified Sources):
Society for Clinical Data Management (SCDM), Good Clinical Data Management Practices (GCDMP),
Chapter: Database Design and Build, Section 6.7 “ Database Performance and Optimization
FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6 “ System
Performance and Data Handling Efficiency
ICH E6 (R2) Good Clinical Practice, Section 5.5 “ Data Handling and Record Integrity
CDISC Operational Data Model (ODM) Implementation Guide “ Bulk Data Transfer and Validation
Considerations
Question # 10
A Data Manager is asked to manage SOPs for a department. Given equal availability of the following
systems, which of the following is the best choice for managing the organizational SOPs?
A. Document management system B. Customized Excel spreadsheet C. Learning management system D. Existing paper filing system
Answer: A Explanation:
The best choice for managing Standard Operating Procedures (SOPs) in a compliant and auditable
manner is a Document Management System (DMS).
According to the GCDMP (Chapter: Regulatory Requirements and Compliance) and ICH E6 (R2), SOPs
must be version-controlled, securely stored, retrievable, and auditable. A validated DMS supports
controlled access, document lifecycle management (draft, review, approval, and archival), and electronic audit trails, ensuring full compliance with FDA 21 CFR Part 11 and Good Documentation
Practices (GDP).
While Learning Management Systems (C) track training, they are not intended for document control.
Spreadsheets (B) and paper systems (D) cannot provide adequate version tracking, access security, or
audit capability required for regulatory inspection readiness.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Regulatory Requirements and
Compliance, Section 5.2 “ SOP Management and Document Control
ICH E6 (R2) GCP, Section 5.5.3 “ Document and Record Management
FDA 21 CFR Part 11 “ Electronic Records and Signatures, Section 11.10 “ System Validation and
Document Controls
Question # 11
For ease of data processing, the study team would like the database codes for a copyrighted rating
scale preprinted on the CRF. What is the most critical task that the CRF designer must do to ensure
the data collected on the CRF for the scale are reliable and will support the results of the final
analysis?
A. Consult the independent source and determine database codes will not influence subject responses. B. Consult the study statistician regarding the change and determine that database codes will not influence the analysis. C. Consult the independent source of the rating scale for approval and document that continued validity of the tool is not compromised. D. Complete the requested changes to the instrument and ensure the correct database codes are associated with the appropriate responses.
Answer: C Explanation:
When using a copyrighted or validated rating scale (e.g., Hamilton Depression Scale, Visual Analog
Pain Scale), any modification to the original instrument, including preprinting database codes on the
CRF, must be approved by the instruments owner or licensing authority to ensure the validity and
reliability of the instrument are not compromised.
According to the GCDMP (Chapter: CRF Design and Data Collection), validated rating scales are
psychometrically tested tools. Any visual or structural modification (such as adding codes, changing
layout, or rewording questions) can invalidate prior validation results. Therefore, the CRF designer
must consult the independent source (copyright holder) for approval and document that the validity
of the tool remains intact.
Merely consulting statisticians (option B) or verifying database alignment (option D) does not ensure
compliance. Thus, Option C ensures scientific and regulatory integrity.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: CRF Design and Data Collection,
Section: Section 6.1 “ Use of Validated Instruments and Rating Scales
ICH E6 (R2) GCP, Section 5.5.3 “ Validation of Instruments and Data Capture Tools
FDA Guidance for Industry: Patient-Reported Outcome Measures “ Use in Medical Product
Development to Support Labeling Claims, Section 4 “ Instrument Modification and Validation
Question # 12
During a database audit, it was determined that there were more errors than expected. Who is
responsible for assessing the overall impact on the analysis of the data?
A. Data Manager B. Statistician C. Quality Auditor D. Investigator
Answer: B Explanation:
The Statistician is responsible for assessing the overall impact of data errors on the analysis and study
results.
According to the Good Clinical Data Management Practices (GCDMP, Chapter: Data Quality
Assurance and Control) and ICH E9 (Statistical Principles for Clinical Trials), while the Data Manager
ensures data accuracy and completeness through cleaning and validation, the Statistician determines
whether the observed data discrepancies are statistically significant or if they may affect the validity,
power, or interpretability of the studys outcomes.
The Quality Auditor (C) identifies and reports issues but does not quantify analytical impact. The
Investigator (D) is responsible for clinical oversight, not statistical assessment. Thus, after a database
audit, the Statistician (B) performs a formal evaluation to determine whether the magnitude and
nature of the errors could bias results or require reanalysis.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Quality Assurance and
Control, Section 7.3 “ Data Audit and Impact Assessment
ICH E9 “ Statistical Principles for Clinical Trials, Section 3.2 “ Data Quality and Analysis Impact
Assessment
FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations “ Data Validation
and Analysis Review
Question # 13
What additional task does the site study coordinator role perform when utilizing an EDC application
compared to paper CRF?
A. Resolving queries B. Data entry C. Data curation D. Medical record abstraction
Answer: B Explanation:
In paper-based trials, site staff (e.g., study coordinators) record data manually on paper Case Report
Forms (CRFs), which are later transcribed by data entry personnel into an electronic database.
However, in EDC-based studies, the site coordinator is directly responsible for entering data into the
EDC system. This eliminates the need for centralized double data entry and shortens data cleaning
timelines.
The GCDMP (Chapter: Electronic Data Capture Systems) states that EDC systems shift certain tasks,
including data entry, initial query response, and source verification preparation, to the site level. Yet,
data entry remains the most significant additional responsibility compared to paper-based studies.
Option A (Query resolution) is performed in both EDC and paper-based systems.
Option C (Data curation) is typically a Data Management function.
Option D (Medical record abstraction) is part of source documentation, not specific to EDC.
Thus, option B (Data entry) is correct ” it is the additional site coordinator duty unique to EDC
environments.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Electronic Data Capture (EDC) Systems, Section 5.3 “ Site Responsibilities
and Workflow Changes
ICH E6(R2) GCP, Section 5.5.3 “ Data Entry and Role Delegation in Computerized Systems
FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6.2 “ SiteLevel Data Entry Controls
Question # 14
It has been identified that ten adverse events were not reported in the trial prior to the database
lock. What action should be taken to determine the next step?
A. Get the AE data entered immediately so the database can be locked again. B. Evaluate the potential effect of the omission on the validity of the safety and efficacy analysis. C. Notify upper management immediately so the monitor can contact the site. D. Check the data from all sites again before relocking the database.
Answer: B Explanation:
When adverse events (AEs) are discovered after a database lock, the appropriate first step is to
evaluate the impact of the missing data on the integrity, safety analysis, and regulatory validity of the
study results.
According to GCDMP (Chapter: Data Quality Assurance and Control), any post-lock data discovery
requires a root cause assessment and impact analysis before deciding whether to unlock the
database. The key question is whether the missing AEs:
Affect primary safety endpoints,
Introduce bias in safety reporting, or
Alter efficacy conclusions.
Based on the assessment, the Data Management and Biostatistics teams determine if unlocking and
correction are justified. Simply entering data immediately (A) or repeating checks (D) without
analysis may violate data control procedures.
Hence, option B is correct ” the first step is to assess the impact on data validity and analysis.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Data Quality Assurance and Control, Section 5.5 “ Post-Lock Findings and
Impact Assessment
ICH E6(R2) GCP, Section 5.1.1 “ Quality Management and Risk Assessment
FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6.5 “ PostLock Data Management
Question # 15
Which of the following tasks would be reasonable during a major upgrade of a clinical data
management system?
A. All of the data formats in the archive should be updated to new standards. B. The ability to access and read the clinical data archive should be tested. C. The data archive should be migrated to an offsite database server. D. All of the case report forms should be pulled and compared to the archive.
Answer: B Explanation:
During a major system upgrade, it is critical to verify that archived data remain accessible, readable,
and intact following the implementation.
According to the GCDMP (Chapter: Database Lock and Archiving), regulatory requirements such as 21
CFR Part 11 and ICH E6(R2) mandate that archived data must remain retrievable in a human-readable
format for the duration of retention (often years after study completion).
Therefore, as part of validation and verification testing, organizations must confirm that existing
archives can still be accessed using the upgraded system or compatible tools.
Option A: Updating archive formats could alter original data integrity (noncompliant).
Option C: Migration offsite is an IT infrastructure task, not directly tied to the upgrade process.
Option D: Comparing CRFs to archives is unnecessary unless data corruption is suspected.
Hence, option B (testing archive accessibility) is the correct and compliant approach. Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Database Lock and Archiving, Section 5.4 “ System Upgrades and Archive
Validation
ICH E6(R2) GCP, Section 5.5.3 “ System Validation and Data Retention
FDA 21 CFR Part 11 “ Data Archiving, Retention, and Retrieval Requirements
Question # 16
Which information should be communicated by the Data Manager at regular intervals throughout a
study?
A. Planned versus actual enrollment B. Site staffing changes C. Percent data entered and clean D. Serious and unexpected safety events
Answer: C Explanation:
The Data Manager (DM) plays a critical role in maintaining transparent communication with the
clinical study team regarding data quality and study progress. One of the most essential metrics
regularly reported by the DM is the percentage of data entered and cleaned.
According to the Good Clinical Data Management Practices (GCDMP, Chapter: Communication and
Study Reporting), these metrics provide insight into study status, data readiness for interim analysis, and timeline predictability for database lock. Regular communication includes:
Percent of CRFs entered and verified
Percent of queries resolved
Outstanding data issues or missing pages
Other options fall outside the Data Managers direct responsibility:
A (Enrollment) is typically reported by clinical operations.
B (Staffing changes) are handled by site management.
D (Safety events) are communicated by the safety/pharmacovigilance team.
Thus, option C correctly reflects the Data Managers responsibility for ongoing study communication.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Communication and Study Reporting, Section 5.3 “ Study Metrics and Status
Updates
ICH E6(R2) GCP, Section 5.1.1 “ Communication and Oversight in Quality Management
FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6.5 “ Data
Status Reporting
Question # 17
What action should be taken regarding the clinical database when MedDRA releases a new version of
its dictionary?
A. Evaluate the extent and impact of the changes. B. Continue using the existing version to code. C. Upgrade the version immediately and recode. D. Identify an alternative dictionary.
Answer: A Explanation:
When a new version of MedDRA (Medical Dictionary for Regulatory Activities) is released, the
correct action is to evaluate the extent and impact of the changes before implementation.
According to the GCDMP (Chapter: Medical Coding and Dictionaries), MedDRA updates are
published twice yearly (March and September). Each release may introduce new terms, modify
hierarchies, or retire old ones. Prior to adopting a new version, the Data Manager and Medical Coder
must:
Assess the number and type of term changes,
Determine the potential effect on ongoing coding consistency, and
Decide whether migration to the new version is warranted mid-study or deferred until database lock.
Immediate recoding (option C) without evaluation may cause inconsistencies and require additional
validation. Continuing with the existing version (option B) may be acceptable short-term but must be
justified. Using an alternative dictionary (option D) is noncompliant, as MedDRA is the regulatory
standard for safety reporting.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Medical Coding and
Dictionaries, Section 6.3 “ Version Control and Impact Assessment
MedDRA Term Selection: Points to Consider (MSSO, Latest Version), Section 3 “ Versioning and
Maintenance
ICH E2B(R3) “ Clinical Safety Data Management: Data Elements for Transmission of Individual Case
Safety Reports
Question # 18
In the transfer of obligations for a double-blind, multi-center trial, a sponsor has maintained the task
of creating the randomization schedule. Who at the sponsor company should create the randomization schedule?
A. The sponsor's project statistical programmer B. The CRO biostatistician C. A sponsor's biostatistician not on the project D. The sponsor's project biostatistician
Answer: C Explanation:
In a double-blind clinical trial, the randomization schedule must be generated by an independent
biostatistician not directly involved in study operations or data management to preserve study
blinding and integrity.
According to ICH E9 and the GCDMP (Chapter: Regulatory Requirements and Compliance),
randomization generation and blinding must be handled in a way that prevents bias or unintentional
unblinding of study personnel. The sponsors biostatistician not assigned to the project (Option C) is
the appropriate person because they have the necessary statistical expertise but remain
operationally independent from study execution.
A project biostatistician (Option D) or programmer (Option A) directly involved in data analysis could
inadvertently compromise blinding. The CRO biostatistician (Option B) should not perform this
function if the sponsor retains randomization responsibility.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Regulatory Requirements and
Compliance, Section 6.4 “ Randomization and Blinding
ICH E9 “ Statistical Principles for Clinical Trials, Section 5.4 “ Randomization Procedures and Blinding
FDA Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics, Section 4.3 “
Maintaining Blinding Integrity
Question # 19
A Clinical Data Manager reads a protocol for a clinical trial to test the efficacy and safety of a new
blood thinner for prevention of secondary cardiac events. The stated endpoint is all-cause mortality
at 1 year. Which data element would be required for the efficacy endpoint?
A. Drug level B. Coagulation time C. Cause of death D. Date of death
Answer: D Explanation:
The efficacy endpoint of all-cause mortality at one year directly depends on the date of death for
each subject, making Option D “ Date of death the required data element.
According to the GCDMP (Chapter: Clinical Trial Protocols and Data Planning) and ICH E3/E9
Guidelines, the primary efficacy analysis must be based on time-to-event data, particularly when the
endpoint involves mortality or survival. The date of death allows accurate calculation of time from
randomization to event, essential for survival analysis (e.g., Kaplan-Meier curves).
While cause of death (C) may be collected for safety or secondary analyses, all-cause mortality
specifically includes any death regardless of cause. Drug levels (A) and coagulation times (B) may
serve as pharmacodynamic or exploratory endpoints but do not directly measure mortality.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Management Planning and
Protocol Review, Section 5.4 “ Defining Data Required for Endpoints
ICH E9 “ Statistical Principles for Clinical Trials, Section 2.3 “ Time-to-Event Endpoints
FDA Guidance for Industry: Clinical Trial Endpoints for Drug Development and Approval
Question # 20
Which metrics report listed below would best help identify trends in the clinical data?
A. Percent of data/visits cleaned B. Last patient/last visit date to data lock date C. Number of subjects screened/enrolled D. Query frequency counts per data element
Answer: D Explanation:
The Query frequency counts per data element (Option D) is the best metric for identifying data
trends and potential systemic data issues in clinical trials.
According to the Good Clinical Data Management Practices (GCDMP, Chapter: Data Quality
Assurance and Control), trend analysis involves identifying recurring data issues across subjects,
sites, or variables to detect training gaps, protocol misinterpretation, or CRF design flaws. A high
number of queries generated for specific fields (e.g., visit date, lab values, or dosing information)
may indicate systemic problems such as unclear CRF instructions or site-level misunderstandings.
While metrics such as percent of data cleaned (A) and time to database lock (B) reflect overall
progress and efficiency, they do not identify specific data pattern issues. The number of subjects
screened/enrolled (C) pertains to recruitment rather than data quality.
Therefore, query frequency per data element provides actionable insights for quality improvement, process refinement, and early identification of potential risks.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Quality Assurance and
Control, Section 6.3 “ Metrics and Trend Analysis
ICH E6 (R2) Good Clinical Practice, Section 5.18.4 “ Risk-Based Quality Review and Data Trends
FDA Guidance for Industry: Oversight of Clinical Investigations “ Risk-Based Monitoring, Section 6 “
Data Metrics and Trend Evaluation
Question # 21
What is the primary benefit of using a standard dictionary for medications?
A. To standardize recording of medications taken by patients across sites B. To facilitate the reporting and analysis of possible drug interactions C. To identify differences in medication components based on country of source D. To improve safety monitoring of patients in a clinical trial setting
Answer: A Explanation:
The primary benefit of using a standard medical dictionary (such as WHO Drug Dictionary, WHO-DD
Enhanced, or RxNorm) in clinical data management is to standardize the recording and
representation of medications taken by study participants across all sites, countries, and data sources
(Option A).
According to the Good Clinical Data Management Practices (GCDMP, Chapter on Medical Coding and
Dictionaries), standardized coding ensures that all variations of drug names ” including brand
names, generic names, abbreviations, and misspellings ” are consistently mapped to a uniform
dictionary term. This harmonization allows for accurate aggregation, analysis, and regulatory
reporting of concomitant medications and investigational products across multiple studies and global
sites.
For example, "Paracetamol" and "Acetaminophen" are the same compound but are known by
different names in different regions. Coding both to the same preferred term (PT) in the WHO Drug
Dictionary ensures that all references are analyzed consistently in safety summaries and
pharmacovigilance reports.
While other options describe secondary benefits:
Option B: Facilitating drug interaction analysis is an important downstream benefit, but it depends on having standardized coding first.
Option C: Identifying differences in medication components by country is a feature of dictionary
metadata but not the primary goal.
Option D: Safety monitoring relies on consistent adverse event and drug data but is an overarching
objective, not the direct function of dictionary coding.
Thus, the primary benefit lies in ensuring consistency, clarity, and interoperability of medication data
across all clinical sites and systems, forming the foundation for reliable safety and efficacy analysis.
Reference (CCDM-Verified Sources):
Society for Clinical Data Management (SCDM), Good Clinical Data Management Practices (GCDMP),
Chapter: Medical Coding and Dictionaries, Section 6.1 “ Purpose and Principles of Coding
WHO Drug Dictionary (WHO-DD) User Manual, Section 2.3 “ Standardization of Medicinal Product
Terminology
ICH E2B (R3) Clinical Safety Data Management “ Data Elements for Transmission of Individual Case
Safety Reports
FDA Study Data Technical Conformance Guide, Section 3.2 “ Use of Controlled Terminology in Drug
and Event Coding
Question # 22
In the EDC database, which factors are considered when defining user roles?
A. Data Entry and Data Review B. Patient Recruitment and Protocol Review C. Protocol Review and Data Entry D. Data Review and Analysis Programming
Answer: A Explanation:
In Electronic Data Capture (EDC) systems, user roles are defined based on the functions and
permissions required for specific study tasks. The most fundamental and universally applicable roles
are Data Entry (performed by site staff) and Data Review (performed by monitors or data managers).
According to the GCDMP (Chapter: Technology and Electronic Data Capture Systems), defining user
roles involves:
Assigning functional access levels (e.g., entry, review, query resolution). Ensuring role-based security to protect data integrity.
Complying with 21 CFR Part 11 and ICH E6(R2) access control standards.
Options B, C, and D include functions (protocol review, analysis programming) not directly controlled
within an EDC system.
Thus, option A (Data Entry and Data Review) correctly represents the two core factors considered
when defining user roles.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Technology and Electronic Data Capture Systems, Section 4.3 “ User Access,
Roles, and Permissions
ICH E6(R2) GCP, Section 5.5.3 “ System Access and Security Controls
FDA 21 CFR Part 11 “ Access Control and Audit Trail Requirements
Question # 23
A Clinical Data Manager is drafting data element definitions for a new study. One of the definitions
provided is:
"Baby's crown to heel length measured lying on back, measured physical quantity, precision of 0.1."
Which of the following is missing from the definition?
A. Discrete values for a drop-down list B. Enumeration C. Data type of the data element D. Unit or dimensionality of measure
Answer: D Explanation:
A complete data element definition in clinical data management should include:
Name and clear description of the data element,
Data type (e.g., numeric, text, date),
Precision or scale (if numeric), and
Unit or dimensionality of measure (e.g., centimeters, inches).
In this example, while the data type (œmeasured physical quantity ) and precision (0.1) are defined,
the unit of measurement (e.g., centimeters or inches) is missing. This omission leads to ambiguity
and could cause serious discrepancies when comparing or analyzing measurements.
The GCDMP (Chapter: Database Design and Build) emphasizes that units and dimensionality must be
explicitly defined and consistently applied in all CRFs, metadata dictionaries, and data
transformations.
Thus, option D (Unit or dimensionality of measure) is correct.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Database Design and Build, Section 5.2 “ Metadata and Data Element
Definitions
CDISC CDASH Implementation Guide, Section 3.3 “ Data Element Metadata Requirements
ICH E6(R2) GCP, Section 5.5.3 “ Data Accuracy and Standardized Definitions
Question # 24
Which statement applies to the CRF Completion Guidelines (CCGs) for a multinational study?
A. CCGs must be translated and back-translated in each local language used in the study B. CCGs must contain the list of acceptable abbreviations to be used in the CRF C. CCGs can instruct sites to write in their local language as long as the CRA is fluent in this language D. CCGs can instruct sites to use any abbreviations if they are documented in the subject source notes
Answer: B Explanation:
The Case Report Form (CRF) Completion Guidelines (CCGs) are critical documents that guide site staff
on how to accurately and consistently record data on CRFs across all participating sites, especially in
multinational trials.
According to the Good Clinical Data Management Practices (GCDMP, Chapter: CRF Design and Data
Collection), one of the key components of the CCGs is a list of acceptable abbreviations and
conventions to be used during CRF entry. This standardization ensures data consistency across
languages and countries, reduces ambiguity during data review, and facilitates database design and
coding accuracy.
While translation (A) may be useful for training materials, it is not required for CCGs unless specified
by regulatory bodies. Options C and D are incorrect because data collection should adhere to
standardized terms in English (or the studys official language) ” allowing free use of local languages
or arbitrary abbreviations introduces inconsistencies.
Hence, option B ” œCCGs must contain the list of acceptable abbreviations to be used in the CRF ”
is correct.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: CRF Design and Data Collection, Section 5.3 “ CRF Completion Guidelines
and Standardization
ICH E6(R2) GCP, Section 5.5.3 “ Consistency and Data Recording Requirements
FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6.2 “ Data
Entry Conventions and Documentation
Question # 25
When a hospitalized subject in a cardiovascular trial experiences a repeated but mild episode of
tachycardia, the physician decides to extend the subject's hospital stay for continued observation.
How would this event be characterized?
A. Serious adverse event B. Adverse event C. Severe adverse event D. Spontaneous adverse event
Answer: A Explanation:
This event qualifies as a Serious Adverse Event (SAE) because it resulted in a prolonged
hospitalization, even though the episode itself was mild.
According to ICH E2A and GCDMP (Chapter: Safety Data Handling and Reconciliation), an adverse
event is considered œserious if it results in any of the following outcomes:
Death,
Life-threatening situation,
Hospitalization or prolongation of existing hospitalization,
Persistent or significant disability/incapacity, or
Congenital anomaly/birth defect.
The severity (mild, moderate, severe) describes intensity, while seriousness describes regulatory
significance and medical outcome. Thus, a mild tachycardia episode leading to extended hospital stay
meets the regulatory definition of an SAE.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Safety Data Handling and
Reconciliation, Section 5.2 “ Definition and Classification of Serious Adverse Events
ICH E2A “ Clinical Safety Data Management: Definitions and Standards for Expedited Reporting,
Section II “ Seriousness Criteria
FDA 21 CFR 312.32 “ IND Safety Reporting: Serious Adverse Event Definitions
Join the Conversation
Be part of the conversation — share your thoughts, reply to others, and contribute your experience.
